Related Experiment Video

Updated: Jun 21, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Antifibrotics for chronic hepatitis C

Paul J Pockros1

  • 1Division of Gastroenterology and Hepatology, The Scripps Research Institute, La Jolla, CA 92037, USA. pockros.paul@scrippshealth.org

Clinics in Liver Disease
|July 25, 2009
PubMed

Insights

Developing new antifibrotic drugs for chronic hepatitis C is crucial, as current treatments targeting liver cells and inflammation have failed. Finding effective endpoints is key to advancing fibrosis reversal therapies.

Area of Science:

  • Hepatology and drug development for liver diseases.

Background:

  • Antifibrotic agents for chronic hepatitis C primarily target hepatic stellate cells, growth factors, inflammation, and extracellular matrix.
  • Existing treatments like interferon-gamma, pegylated interferon, and caspase inhibitors have shown limited efficacy.
  • A significant unmet need exists for antifibrotic therapies in patients unresponsive or ineligible for antiviral treatments.

Purpose of the Study:

  • To highlight the need for novel antifibrotic agents for chronic hepatitis C.
  • To identify the challenges in developing and testing these agents, particularly the lack of suitable endpoints.
  • To emphasize the importance of establishing clear endpoints for advancing drug development.

Main Methods:

  • Review of existing antifibrotic strategies and their limitations in chronic hepatitis C.
  • Analysis of therapeutic targets including hepatic stellate cells and fibrogenic pathways.
  • Discussion of clinical trial challenges related to endpoint determination.

Main Results:

  • Current antifibrotic strategies targeting hepatic stellate cells, TGF-beta, inflammation, and ECM have not yielded effective treatments.
  • Several studied agents, including interferon-gamma and caspase inhibitors, have failed to demonstrate efficacy.
  • A major obstacle in developing new drugs is the difficulty in establishing appropriate histologic or clinical endpoints within a practical timeframe.

Conclusions:

  • There is a critical need for antifibrotic drugs that can inhibit or reverse liver fibrosis in chronic hepatitis C.
  • Effective therapies are essential for patients with treatment failure or contraindications to antiviral therapy.
  • Advancement in identifying suitable endpoints for clinical studies is paramount to promote the development of novel antifibrotic agents.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...